BiotechTube

dabrafenib/trametinib

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer

Trial Timeline

Jan 1, 2023 → Jan 1, 2028

NCT ID
NCT06079333

About dabrafenib/trametinib

dabrafenib/trametinib is a phase 2 stage product being developed by Novartis for Anaplastic Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06079333. Target conditions include Anaplastic Thyroid Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06079333Phase 2Recruiting

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
LDK378 + AUY922NovartisPhase 1
33
ceritinibNovartisPre-clinical
23
LDK378NovartisPhase 1
33
CeritinibNovartisPhase 2
52
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
33
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
77
Sunitinib MalatePfizerPhase 2
51
Crizotinib (PF-02341066)PfizerPhase 2
51
LorlatinibPfizerPhase 2
51
CrizotinibPfizerPhase 1/2
40
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
32
Etirinotecan pegolNektar TherapeuticsPhase 2
47
BevacizumabNovocurePhase 2
47

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85